You're viewing our updated article page. If you need more time to adjust, you can return to the old layout.

CORRECTION article

Front. Ophthalmol., 16 July 2025

Sec. Inflammatory Eye Diseases

Volume 5 - 2025 | https://doi.org/10.3389/fopht.2025.1641164

Correction: The role of IL-6 in thyroid eye disease: an update on emerging treatments

  • 1. Jennifer Murdock MD, PLLC, Miami, FL, United States

  • 2. School of Medicine, West Virginia University, Morgantown, WV, United States

  • 3. Tourmaline Bio, Inc., New York, NY, United States

  • 4. Department of Surgery, Sharp Grossmont Hospital for Neuroscience, La Mesa, CA, United States

Article metrics

View details

1

Citations

1,2k

Views

259

Downloads

Author Jennifer Murdock was erroneously assigned to affiliation “1Oculofacial Plastic Surgery, Miami, FL, United States, and 2Thrive Health, West Vancouver, BC, Canada” instead of “1Jennifer Murdock MD, PLLC, Miami, FL, United States”. This affiliation has now been updated for author Jennifer Murdock.

The conflict of interest statement has been corrected to: AL, BH, CA, CT, JW, and KE are employees of Tourmaline Bio, Inc. JM is a medical director for Thrive Health, which administers IV infusions of teprotumumab, was a consultant for Horizon/Amgen until September 2023, and has a CDA with Tourmaline Bio, Inc. for planning internal consulting and education. JM is also the CEO of Jennifer Murdock MD, PLLC. KC is a consultant and principal investigator for Horizon/Amgen, Viridian, Acelyrin, Genentech/Roche, Immunovant, ArgenX, and Tourmaline Bio, Inc. JN has received research funding from Tourmaline Bio, Inc.

The original article has been updated.

Statements

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

IL-6, IL-6R, thyroid eye disease (TED), Graves’ ophthalmopathy, Graves’ orbitopathy, Graves’ disease, thyroid-associated orbitopathy (TAO)

Citation

Murdock J, Nguyen J, Hurtgen BJ, Andorfer C, Walsh J, Lin A, Tubbs C, Erickson K and Cockerham K (2025) Correction: The role of IL-6 in thyroid eye disease: an update on emerging treatments. Front. Ophthalmol. 5:1641164. doi: 10.3389/fopht.2025.1641164

Received

04 June 2025

Accepted

10 June 2025

Published

16 July 2025

Approved by

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Volume

5 - 2025

Updates

Copyright

*Correspondence: Kristine Erickson,

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics